nach oben

Digestive Diseases and Sciences

Erschienen in:

01.10.2012 | Editorial

Gastric Cardia Cancer: How Much Is It from Fat?

verfasst von: Preetika Sinh, Prateek Sharma

Erschienen in: Digestive Diseases and Sciences | Ausgabe 10/2012

Einloggen, um Zugang zu erhalten

Excerpt

The overall age-adjusted incidence of gastric cancer has decreased in the United States from 11.7 to 7.1 persons per 100,000 from 1975 to 2008 according to the surveillance epidemiology and end results (SEER-9) database [1]. Similar trends have been observed worldwide. Although the incidence of gastric non-cardia adenocarcinoma (GNCA) has decreased worldwide the incidence of gastric cardia adenocarcinoma (GCA) has steadily increased over the last three to four decades along with a rise in esophageal adenocarcinoma (EAC) incidence [2, 3]. …

National Cancer Institute. SEER stat fact sheets: stomach. 2012. Available at: http://seer.cancer.gov/statfacts/html/stomach.html#incidence-mortality. Accessed 20 July 2012.

Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991;265:1287–1289.PubMedCrossRef

Botterweck AA, Schouten LJ, Volovics A, Dorant E, van Den Brandt PA. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol. 2000;29:645–654.PubMedCrossRef

El-Serag HB, Mason AC, Petersen N, Key CR. Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut. 2002;50:368–372.PubMedCrossRef

MacInnis RJ, English DR, Hopper JL, Giles GG. Body size and composition and the risk of gastric and oesophageal adenocarcinoma. Int J Cancer J Int Cancer. 2006;118:2628–2631.CrossRef

O’Doherty MG, Freedman ND, Hollenbeck AR, Schatzkin A, Abnet CC. A prospective cohort study of obesity and risk of oesophageal and gastric adenocarcinoma in the NIH-AARP Diet and Health Study. Gut. 2011.

Abnet CC, Freedman ND, Hollenbeck AR, Fraumeni JF Jr, Leitzmann M, Schatzkin A. A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma. Eur J Cancer. 2008;44:465–471.PubMedCrossRef

The International Classification of Diseases, 9th revision. Clinical Modification, 2nd ed. City: Public Health Service, US Government Printing Office; 1980:80–1260.

International Classification of Diseases for Oncology. Geneva: World Health Organization; 1976.

10.

Ekstrom AM, Signorello LB, Hansson LE, Bergstrom R, Lindgren A, Nyren O. Evaluating gastric cancer misclassification: a potential explanation for the rise in cardia cancer incidence. J Natl Cancer Inst. 1999;91:786–790.PubMedCrossRef

11.

Siewert JR, Feith M, Stein HJ. Biologic and clinical variations of adenocarcinoma at the esophagogastric junction: relevance of a topographic-anatomic subclassification. J Surg Oncol (Semin). 2005;90:139–146; discussion 146.

12.

Wang Y, Beydoun MA. The obesity epidemic in the United States—gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol Rev. 2007;29:6–28.PubMedCrossRef

13.

Polednak AP. Estimating the number of US incident cancers attributable to obesity and the impact on temporal trends in incidence rates for obesity-related cancers. Cancer Detect Prev. 2008;32:190–199.PubMedCrossRef

14.

Lindblad M, Rodriguez LA, Lagergren J. Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case–control study. Cancer Causes Control (CCC). 2005;16:285–294.CrossRef

15.

Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15:872–878.PubMedCrossRef

16.

Merry AH, Schouten LJ, Goldbohm RA, van den Brandt PA. Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardia: a prospective cohort study. Gut. 2007;56:1503–1511.PubMedCrossRef

17.

Corley DA, Kubo A, Zhao W. Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomarkers Prev. 2008;17:352–358.PubMedCrossRef

18.

Cho Y, Lee DH, Oh HS, et al. Higher prevalence of obesity in gastric cardia adenocarcinoma compared to gastric non-cardia adenocarcinoma. Dig Dis Sci. 2012. (Epub ahead of print). doi:10.1007/s10620-012-2095-6.

19.

Deans C, Yeo M, Soe M, Shabbir A, Ti T, So J. Cancer of the gastric cardia is rising in incidence in an Asian population and is associated with adverse outcome. World J Surg. 2011;35:617–624.PubMedCrossRef

20.

Kusano C, Gotoda T, Khor CJ, et al. Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan. J Gastroenterol Hepatol. 2008;23:1662–1665.PubMedCrossRef

21.

Tony J, Kumar SK, Thomas V. Time trends and pathological profile of carcinoma lower oesophagus and gastro-oesophageal junction over the last 20 years—an experience from South India. Trop Gastroenterol Off J Dig Dis Found. 2007;28:113–116.

22.

Zhou Y, Zhang Z, Zhang Z, et al. A rising trend of gastric cardia cancer in Gansu Province of China. Cancer Lett. 2008;269:18–25.PubMedCrossRef

23.

Chang SS, Lu CL, Chao JY, et al. Unchanging trend of adenocarcinoma of the esophagus and gastric cardia in Taiwan: a 15-year experience in a single center. Dig Dis Sci. 2002;47:735–740.PubMedCrossRef

24.

Hasegawa S, Yoshikawa T, Cho H, Tsuburaya A, Kobayashi O. Is adenocarcinoma of the esophagogastric junction different between Japan and western countries? The incidence and clinicopathological features at a Japanese high-volume cancer center. World J Surg. 2009;33:95–103.PubMedCrossRef

25.

Zhang J, Su XQ, Wu XJ, et al. Effect of body mass index on adenocarcinoma of gastric cardia. World J Gastroenterol. 2003;9:2658–2661.PubMed

26.

Chow W-H, Blaser MJ, Blot WJ, et al. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res. 1998;58:588–590.PubMed

27.

Wu AH, Crabtree JE, Bernstein L, et al. Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. Int J Cancer. 2003;103:815–821.PubMedCrossRef

28.

Beddy P, Howard J, McMahon C, et al. Association of visceral adiposity with oesophageal and junctional adenocarcinomas. Brit J Surg. 2010;97:1028–1034.PubMedCrossRef

29.

Akiyama T, Yoneda M, Maeda S, Nakajima A, Koyama S, Inamori M. Visceral obesity and the risk of Barrett’s esophagus. Digestion. 2011;83:142–145.PubMedCrossRef

30.

Lagergren J. Influence of obesity on the risk of esophageal disorders. Nat Rev Gastroenterol Hepatol. 2011;8:340–347.PubMedCrossRef

31.

Cameron AJ, Lomboy CT, Pera M, Carpenter HA. Adenocarcinoma of the esophagogastric junction and Barrett’s esophagus. Gastroenterology. 1995;109:1541–1546.PubMedCrossRef

32.

Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825–831.PubMedCrossRef

33.

Cook MB, Kamangar F, Whiteman DC, et al. Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst. 2010;102:1344–1353.PubMedCrossRef

34.

Tramacere I, La Vecchia C, Negri E. Tobacco smoking and esophageal and gastric cardia adenocarcinoma: a meta-analysis. Epidemiology. 2011;22:344–349.PubMedCrossRef

35.

Liao LM, Vaughan TL, Corley DA, et al. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology. 2012;142:442–452, e445; quiz e422–e443.

36.

Kubo A, Corley DA, Jensen CD, Kaur R. Dietary factors and the risks of oesophageal adenocarcinoma and Barrett’s oesophagus. Nutr Res Rev. 2010;23:230–246.PubMedCrossRef

37.

Chow WH, Blaser MJ, Blot WJ, et al. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res. 1998;58:588–590.PubMed

38.

Islami F, Kamangar F. Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev Res (Phila). 2008;1:329–338.CrossRef

Titel: Gastric Cardia Cancer: How Much Is It from Fat?
verfasst von: Preetika Sinh
Prateek Sharma
Publikationsdatum: 01.10.2012
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 10/2012
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-012-2324-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2012

Effects of Helicobacter pylori γ-Glutamyltranspeptidase on Apoptosis and Inflammation in Human Biliary Cells

Superiority of the DNA Amplification Assay for the Diagnosis of C. difficile Infection: A Clinical Comparison of Fecal Tests

IL-1 Receptor Antagonist Blocks the Lipopolysaccharide-Induced Inhibition of Gastric Motility in Freely Moving Conscious Rats

Soluble Epoxide Hydrolase Gene Deficiency or Inhibition Attenuates Chronic Active Inflammatory Bowel Disease in IL-10(−/−) Mice

Variables Associated with Stress Ulcer Prophylaxis Misuse: A Retrospective Analysis